Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma

  • Pierpaolo Alongi
  • Laura Evangelista
  • Federico Caobelli
  • Marianna Spallino
  • Luigi Gianolli
  • Massimo Midiri
  • Maria Picchio
Original Article

Abstract

Aim

The aim of this bicentric retrospective study was to assess the diagnostic performance, the prognostic value, the incremental prognostic value and the impact on therapeutic management of 18F-FDG PET/CT in patients with suspected recurrent germinal cell testicular carcinoma (GCT).

Materials and methods

From the databases of two centers including 31,500 18F-FDG PET/CT oncological studies, 114 patients affected by GCT were evaluated in a retrospective study. All 114 patients underwent 18F-FDG PET/CT for suspected recurrent disease. Diagnostic performance of visually interpreted 18F-FDG PET/CT and potential impact on the treatment decision were assessed using histology (17 patients), other diagnostic imaging modalities (i.e., contrast enhanced CT in 89 patients and MRI in 15) and clinical follow-up (114 patients) as reference. Progression-free survival (PFS) and overall survival (OS) rates were computed by means of Kaplan-Meier survival analysis. The progression rate (Hazard Ratio-HR) was determined using univariate Cox regression analysis by considering various clinical variables.

Results

Recurrent GCT was confirmed in 47 of 52 patients with pathological 18F-FDG PET/CT findings, by means of histology in 18 patients and by other diagnostic imaging modalities/follow-up in 29. Sensitivity, specificity, accuracy, positive and negative likelihood ratio (LR+ and LR-, respectively), pre-test Odds-ratio and post-test Odds-ratio of 18FDG PET/CT were 86.8%, 90.2%, 88.4%, 8.85, 0.14, 0.85, 8.85, respectively.18F-FDG PET/CT impacted significantly on therapeutic management in 26/114 (23%) cases (from palliative to curative in 12 patients, from “wait and watch” to new chemotherapy in six patients and the “wait-and-watch” approach in eight patients with unremarkable findings). At 2 and 5-year follow-up, PFS was significantly longer in patients with a negative than a pathological 18F-FDG PET/CT scan (98% and 95% vs 48% and 38%, respectively; p = 0.02). An unremarkable scan was associated also with a longer OS (98% after 2 years and 95% after 5 years, p = 0.02). At univariate Cox regression analysis, a pathological 18F-FDG PET/CT scan was associated with an increased risk of disease progression (HR = 24.3, CI 95% 14.1-40.6; p = 0.03) and lower OS (HR = 17.3 CI 95% 4,9-77; p < 0.001). Its prognostic value was confirmed also if tested against advanced disease at diagnosis and rising Human Chorionic Gonadotropin Beta (HCGB) or Alpha-Fetoprotein (AFP) (HR = 7.3 for STAGE III-PET+, p = 0.03; HR = 14.3 elevated HCGB-PET+, p = 0.02; HR 10.7 elevated AFP-PET+, p = 0.01) At multivariate analysis, only a pathological 18F-FDG PET/CT scan and advanced disease in terms of TNM staging were predictors of disease progression and OS. 18F-FDG PET/CT showed incremental value over other variables both in predicting PFS (chi-square from 24 to 40, p < 0.001) and OS (chi-square from 32 to 38, p = 0.003).

Conclusion

18F-FDG PET/CT has a very good diagnostic performance in patients with suspected recurrent GCT and has an important prognostic value in assessing the rate of PFS and OS. Furthermore, 18F-FDG PET/CT impacted the therapeutic regimen in 23% of patients, thus providing a significant impact in the restaging process.

Keywords

Germinal cell testicular carcinoma 18F-FDG-PET/CT Restaging Prognostic role Therapeutic management 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

The authors have no disclosure of any personal or financial support for this multicenter study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included

in the study.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU guidelines on testicular cancer: 2011 update. European Association of Urology. Actas Urol españolas. 2012;36:127–45.Google Scholar
  3. 3.
    Carver BS, Sheinfeld J. Germ cell tumors of the testis. Ann Surg Oncol. 2005;12:871–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Coursey Moreno C, Small WC, Camacho JC, Master V, Kokabi N, Lewis M, et al. Testicular tumors: what radiologists need to know--differential diagnosis, staging, and management. Radiographics. 35:400–15.Google Scholar
  5. 5.
    Brunereau L, Bruyère F, Linassier C, Baulieu J-L. The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging. 2012;93:310–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Caobelli F, Alongi P, Evangelista L, Picchio M, Saladini G, Rensi M, et al. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. Eur J Nucl Med Mol Imaging. 2016;43:404–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Alongi P, Picchio M, Zattoni F, Spallino M, Gianolli L, Saladini G, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2015.Google Scholar
  8. 8.
    Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014;6:1821–89.CrossRefGoogle Scholar
  9. 9.
    Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005;5:869–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Barlow LJ, Badalato GM, McKiernan JM. Serum tumor markers in the evaluation of male germ cell tumors. Nat Rev Urol. 2010;7:610–7. 6 CrossRefPubMedGoogle Scholar
  11. 11.
    Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.CrossRefPubMedGoogle Scholar
  12. 12.
    Stomper PC, Kalish LA, Garnick MB, Richie JP, Kantoff PW. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded? Radiology. 1991;180:711–4.CrossRefPubMedGoogle Scholar
  13. 13.
    Treglia G, Sadeghi R, Annunziata S, Caldarella C, Bertagna F, Giovanella L. Diagnostic performance of fluorine-18-Fluorodeoxyglucose positron emission tomography in the Postchemotherapy Management of Patients with Seminoma: systematic review and meta-analysis. Biomed Res Int. 2014;2014:1–11.CrossRefGoogle Scholar
  14. 14.
    Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch J-R, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64.CrossRefPubMedGoogle Scholar
  15. 15.
    Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–68.CrossRefPubMedGoogle Scholar
  16. 16.
    Oechsle K, Hartmann M, Brenner W, Venz S, Weissbach L, Franzius C, et al. [ 18 F]Fluorodeoxyglucose positron emission tomography in Nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26:5930–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Claussen CD, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer. 2002;86:506–11.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Alongi P, Caobelli F, Gentile R, Stefano A, Russo G, Albano D, et al. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2017;44:224–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentIRCSS San Raffaele Scientific InstituteMilanItaly
  2. 2.Department of Radiological Sciences, Nuclear Medicine UnitSan Raffaele G.Giglio InstituteCefalùItaly
  3. 3.Nuclear Medicine and Molecular Imaging UnitVeneto Institute of Oncology IOV – IRCCSPaduaItaly
  4. 4.Department of Nuclear MedicineBasel University HospitalBaselSwitzerland
  5. 5.University of Milano-BicoccaMilanItaly
  6. 6.Department of Radiology, DIBIMEDUniversity of PalermoPalermoItaly

Personalised recommendations